Exact Sciences Corporation
NASDAQ: EXAS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Kevin T. Conroy
- Employees
- 6,900
- Headquarters
- Madison, United States
- IPO year
- 2001
- Market cap
- $20.0B
- Website
- https://www.exactsciences.com
Loading EXAS…
Loading profile data…Frequently asked questions about EXAS
What does Exact Sciences Corporation (EXAS) do?
Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancero...
Where does EXAS trade?
Exact Sciences Corporation (EXAS) trades on the NASDAQ Capital Market.
What sector is EXAS in?
Exact Sciences Corporation (EXAS) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Exact Sciences Corporation?
Kevin T. Conroy is the chief executive officer of Exact Sciences Corporation (EXAS).
Where is Exact Sciences Corporation headquartered?
Exact Sciences Corporation is headquartered in United States.
Does EXAS pay a dividend?
Exact Sciences Corporation (EXAS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EXAS go public?
Exact Sciences Corporation (EXAS) completed its initial public offering in 2001.